News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Next Pharmaceuticals Signs Exclusive Supply Agreement With Kelatron For Its New Patented, Chromulin(TM)


1/22/2007 1:24:13 PM

CARLSBAD, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today that it has signed an exclusive supply agreement with Kelatron for its patented Chromulin™ (U.S. Patent No. 6,689,383), an exciting breakthrough in chromium nutrition. Chromulin™ (chromium histidine) is water soluble and the most bio-available form of chromium, making it ideal for beverage applications and foods targeting any aspect of carbohydrate, protein, and fat metabolism.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES